8-K: FOXO Technologies Licenses Epigenetics IP to Founder

FOXO Technologies has entered into an exclusive licensing agreement with founder Jon R. Sabes to commercialize its epigenetics intellectual property portfolio.

Summary

• FOXO Technologies and its subsidiary, FOXO Labs, granted an exclusive, worldwide license for its epigenetics intellectual property to LongevityFP Technologies, LLC, an entity controlled by founder Jon R. Sabes.
• The licensed portfolio includes two U.S. patents, a 13,000+ individual epigenetic dataset, and proprietary machine learning models.
• LongevityFP Technologies will pay a 3% royalty on net revenues derived from the licensed IP, capped at an aggregate of $1,300,000.
• The agreement grants LongevityFP Technologies a ten-year option to acquire majority ownership of FOXO Labs, which would result in FOXO retaining a 40% equity interest in the enterprise.
• The deal includes mutual releases, resolving all prior legal and business matters between the company and Mr. Sabes.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-positive development; while it provides a path to monetize dormant assets and resolve litigation, the low royalty cap suggests limited long-term financial impact.

Positives

• Provides a potential royalty revenue stream from previously uncommercialized technology.
• Allows management to focus resources on core healthcare services operations, such as hospital and recovery center management.
• Retains a 40% equity upside in the epigenetics technology should the acquisition option be exercised.
• Resolves outstanding legal and business disputes with the company's founder.

Negatives

• The royalty revenue is capped at a relatively low $1.3 million, limiting the total financial upside from the license.
• The company effectively offloads the commercialization risk and control of its primary biotech intellectual property.
• The potential loss of majority control over FOXO Labs if the acquisition option is exercised.

Risks

• The commercial success of the licensed technology is speculative and dependent on the licensee's ability to execute.
• The company has a history of losses and may not achieve or maintain future profitability.
• The enforceability of the intellectual property and potential for future infringement claims.
• Regulatory and competitive risks inherent in the life insurance and biotechnology industries.

Future Outlook

The company intends to focus on its core healthcare services, including hospital operations and behavioral health facilities, while relying on the licensee to commercialize the epigenetics platform.

Management Comments

• Seamus Lagan: We are excited to join forces with former FOXO CEO, Jon Sabes, to unlock value from technology that has not been commercialized under the current corporate structure.
• Jon R. Sabes: Recent advances in AI and research on epigenetic biomarkers have strengthened the original business case, and I am committed to working diligently to create value for stockholders.

Industry Context

StockSavvy.ai notes that this move represents a strategic pivot for FOXO, shifting from a direct-to-market biotech developer to a licensing model, which is common for companies struggling to bridge the gap between R&D and commercial revenue in the highly regulated life insurance sector.

Comparison to Industry Standards

• The licensing model is a standard approach for small-cap biotech firms to monetize IP without incurring the high costs of clinical trials or commercial infrastructure.
• The 3% royalty rate is on the lower end of typical industry standards for exclusive technology licenses, reflecting the early-stage or unproven nature of the commercial application.

Corporate Governance

Legal Proceedings

• The agreement includes mutual releases that resolve all prior matters between the company and Jon R. Sabes.

Related Party Transactions

• The agreement is with Jon R. Sabes, the company's founder and former CEO, and an entity he controls.

Stakeholder Impact

• Shareholders may benefit from the potential monetization of previously stagnant IP.
• Management can focus on core hospital and recovery center operations.

Next Steps

• Execution of the commercialization plan by LongevityFP Technologies.
• Monitoring of potential exercise of the acquisition option by the licensee over the next ten years.

Key Dates

Recommendation

The deal provides clarity and potential revenue, but the financial upside is capped and the company's core business remains in a challenging healthcare services environment.

Keywords

FOXO Technologies, Epigenetics, Intellectual Property, Licensing Agreement, Biotechnology, Jon Sabes, Life Insurance Underwriting